Progress in structure based drug design for G protein-coupled receptors

Journal of Medicinal Chemistry

Volumn 54, Issue 13, 2011, Pages 4283-4311

  Congreve, Miles ^a   Langmead, Christopher J ^a   Mason, Jonathan S ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ALMOTRIPTAN; ALOSETRON; ALPRENOLOL; ALVIMOPAN; ARFORMOTEROL; ARIPIPRAZOLE; ARMODAFINIL; ASENAPINE; BACTERIORHODOPSIN; BETOTASTINE; BIMATOPROST; BLONANSERIN; CAFFEINE; CARAZALOL; CARAZOLOL; CEVIMELINE; CYANOPINDOLOL; DARIFENACIN; DESLORATADINE; DOBUTAMINE; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; LIRAGLUTIDE; SALBUTAMOL; TIMOLOL; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING SITE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; GENOME; HUMAN; LIGAND BINDING; LIPOPHILICITY; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79960176452     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200371q     Document Type: Review

References (185)

1. Bikker, J. A.; Trumpp-Kallmeyer, S.; Humblet, C. G-Protein coupled receptors: models, mutagenesis, and drug design J. Med. Chem. 1998, 41 (16) 2911-2927 (Pubitemid 28359925)
2. Henderson, R.; Schertler, G. F. The structure of bacteriorhodopsin and its relevance to the visual opsins and other seven-helix G-protein coupled receptors Philos. Trans. R. Soc. London, Ser. B 1990, 326 (1236) 379-389
3. Schertler, G. F.; Villa, C.; Henderson, R. Projection structure of rhodopsin Nature 1993, 362 (6422) 770-772 (Pubitemid 23125985)
4. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46 (1-3) 3-26 (Pubitemid 33653411)
5. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6 (11) 881-890 (Pubitemid 350042396)
6. Empfield, J. R.; Leeson, P. D. Lessons learned from candidate drug attrition IDrugs 2010, 13 (12) 869-873
7. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discovery 2008, 7 (4) 339-357
8. Hopkins, A. L.; Groom, C. R. The druggable genome Nat. Rev. Drug Discovery 2002, 1 (9) 727-730 (Pubitemid 37361545)
9. Briones, M.; Bajaj, M. Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus Expert Opin. Pharmacother. 2006, 7 (8) 1055-1064 (Pubitemid 43949943)
10. Lewiecki, E. M. Emerging drugs for postmenopausal osteoporosis Expert Opin. Emerging Drugs 2009, 14 (1) 129-144
11. Bhattacharya, S.; Subramanian, G.; Hall, S.; Lin, J.; Laoui, A.; Vaidehi, N. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1 J. Comput.-Aided Mol. Des. 2010, 24 (8) 659-674
12. Tellew, J. E.; Lanier, M.; Moorjani, M.; Lin, E.; Luo, Z.; Slee, D. H.; Zhang, X.; Hoare, S. R.; Grigoriadis, D. E., St; Denis, Y.; Di Fabio, R.; Di Modugno, E.; Saunders, J.; Williams, J. P. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties Bioorg. Med. Chem. Lett. 2010, 20 (24) 7259-7264
13. Yona, S.; Lin, H. H.; Siu, W. O.; Gordon, S.; Stacey, M. Adhesion-GPCRs: emerging roles for novel receptors Trends Biochem. Sci. 2008, 33 (10) 491-500
14. Pin, J. P.; Galvez, T.; Prezeau, L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors Pharmacol. Ther. 2003, 98 (3) 325-354 (Pubitemid 36638547)
15. McLean, B. N. Intrathecal baclofen in severe spasticity Br. J. Hosp. Med. 1993, 49 (4) 262-267
16. Iqbal, J.; Zaidi, M.; Schneider, A. E. Cinacalcet hydrochloride (Amgen) IDrugs 2003, 6 (6) 587-592
17. Kenakin, T. Principles: receptor theory in pharmacology Trends Pharmacol. Sci. 2004, 25 (4) 186-192 (Pubitemid 38519909)
18. Park, P. S.; Lodowski, D. T.; Palczewski, K. Activation of G protein-coupled receptors: beyond two-state models and tertiary conformational changes Annu. Rev. Pharmacol. Toxicol. 2008, 48, 107-141 (Pubitemid 351738151)
19. Alkhalfioui, F.; Magnin, T.; Wagner, R. From purified GPCRs to drug discovery: the promise of protein-based methodologies Curr. Opin. Pharmacol. 2009, 9 (5) 629-635
20. Keov, P.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective Neuropharmacology 2011, 60 (1) 24-35
21. La Motta, C.; Sartini, S.; Morelli, M.; Taliani, S.; Da Settimo, F. Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands Curr. Top. Med. Chem. 2010, 10 (10) 976-992
22. Conn, P. J.; Jones, C. K.; Lindsley, C. W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 2009, 30 (3) 148-155
23. Schetz, J. A. Allosteric modulation of dopamine receptors Mini-Rev. Med. Chem. 2005, 5 (6) 555-561 (Pubitemid 40754169)
24. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8 (1) 41-54
25. Nemeth, E. F.; Heaton, W. H.; Miller, M.; Fox, J.; Balandrin, M. F.; Van Wagenen, B. C.; Colloton, M.; Karbon, W.; Scherrer, J.; Shatzen, E.; Rishton, G.; Scully, S.; Qi, M.; Harris, R.; Lacey, D.; Martin, D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl J. Pharmacol. Exp. Ther. 2004, 308 (2) 627-635 (Pubitemid 38134225)
26. Urwyler, S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 2011, 63 (1) 59-126
27. Langmead, C. J.; Christopoulos, A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox Trends Pharmacol. Sci. 2006, 27 (9) 475-481 (Pubitemid 44233695)
28. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51 (Pubitemid 46277033)
29. Lazareno, S.; Popham, A.; Birdsall, N. J. Allosteric interactions of staurosporine and other indolocarbazoles with N -[methyl-(3) H ]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site Mol. Pharmacol. 2000, 58 (1) 194-207
30. Leach, K.; Loiacono, R. E.; Felder, C. C.; McKinzie, D. L.; Mogg, A.; Shaw, D. B.; Sexton, P. M.; Christopoulos, A. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties Neuropsychopharmacology 2010, 35 (4) 855-869
31. Pagano, A.; Ruegg, D.; Litschig, S.; Stoehr, N.; Stierlin, C.; Heinrich, M.; Floersheim, P.; Prezeau, L.; Carroll, F.; Pin, J. P.; Cambria, A.; Vranesic, I.; Flor, P. J.; Gasparini, F.; Kuhn, R. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[ b ]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors J. Biol. Chem. 2000, 275 (43) 33750-33758
32. Schaffhauser, H.; Rowe, B. A.; Morales, S.; Chavez-Noriega, L. E.; Yin, R.; Jachec, C.; Rao, S. P.; Bain, G.; Pinkerton, A. B.; Vernier, J. M.; Bristow, L. J.; Varney, M. A.; Daggett, L. P. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2 Mol. Pharmacol. 2003, 64 (4) 798-810 (Pubitemid 37153048)
33. Binet, V.; Brajon, C.; Le Corre, L.; Acher, F.; Pin, J. P.; Prezeau, L. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor J. Biol. Chem. 2004, 279 (28) 29085-29091 (Pubitemid 38915779)
34. Nicholls, D. J.; Tomkinson, N. P.; Wiley, K. E.; Brammall, A.; Bowers, L.; Grahames, C.; Gaw, A.; Meghani, P.; Shelton, P.; Wright, T. J.; Mallinder, P. R. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2 Mol. Pharmacol. 2008, 74 (5) 1193-1202
35. Valant, C.; Gregory, K. J.; Hall, N. E.; Scammells, P. J.; Lew, M. J.; Sexton, P. M.; Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand J. Biol. Chem. 2008, 283 (43) 29312-29321
36. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the human dopamine d3 receptor in complex with a d2/d3 selective antagonist Science 2010, 330 (6007) 1091-1095
37. Hanson, M. A.; Stevens, R. C. Discovery of new GPCR biology: one receptor structure at a time Structure 2009, 17 (1) 8-14
38. Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of G-protein-coupled receptors Nature 2009, 459 (7245) 356-363
39. Kobilka, B.; Schertler, G. F. New G-protein-coupled receptor crystal structures: insights and limitations Trends Pharmacol. Sci. 2008, 29 (2) 79-83
40. Sabio, M.; Topiol, S. W. X-ray Structure Developments for GPCR Drug Targets. In GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions; Gilchrist, A., Ed.; John Wiley and Sons: Hoboken, NJ, 2010; pp 434-459.
41. Ballesteros, J. A.; Weinstein, H.; Stuart, C. S. Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors. In Methods in Neurosciences; Academic Press: San Diego, CA, 1995; Vol. 25, pp 366-428.
42. Bridges, T. M.; Lindsley, C. W. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 2008, 3 (9) 530-541
43. Valant, C.; Sexton, P. M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs Mol. Interventions 2009, 9 (3) 125-135
44. Holst, B.; Nygaard, R.; Valentin-Hansen, L.; Bach, A.; Engelstoft, M. S.; Petersen, P. S.; Frimurer, T. M.; Schwartz, T. W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors J. Biol. Chem. 2010, 285 (6) 3973-3985
45. Nygaard, R.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Schwartz, T. W. Ligand binding and micro-switches in 7TM receptor structures Trends Pharmacol. Sci. 2009, 30 (5) 249-259
46. Standfuss, J.; Edwards, P. C.; D'Antona, A.; Fransen, M.; Xie, G.; Oprion, D.; Schertler, G. F. The structural basis of agonist-induced activation in constitutively active rhodopsin Nature 2011, 471 (7340) 656-660
47. Vogel, R.; Mahalingam, M.; Ludeke, S.; Huber, T.; Siebert, F.; Sakmar, T. P. Functional role of the "ionic lock"-an interhelical hydrogen-bond network in family A heptahelical receptors J. Mol. Biol. 2008, 380 (4) 648-655
48. Hofmann, K. P.; Scheerer, P.; Hildebrand, P. W.; Choe, H. W.; Park, J. H.; Heck, M.; Ernst, O. P. A G protein-coupled receptor at work: the rhodopsin model Trends Biochem. Sci. 2009, 34 (11) 540-552
49. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Crystal structure of opsin in its G-protein-interacting conformation Nature 2008, 455 (7212) 497-502
50. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28 (7) 849-857 (Pubitemid 15012490)
51. Sciabola, S.; Stanton, R. V.; Mills, J. E.; Flocco, M. M.; Baroni, M.; Cruciani, G.; Perruccio, F.; Mason, J. S. High-throughput virtual screening of proteins using GRID molecular interaction fields J. Chem. Inf. Model. 2010, 50 (1) 155-169
52. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor Science 2000, 289 (5480) 739-745 (Pubitemid 30650186)
53. Patny, A.; Desai, P. V.; Avery, M. A. Homology modeling of G-protein-coupled receptors and implications in drug design Curr. Med. Chem. 2006, 13 (14) 1667-1691 (Pubitemid 43821698)
54. Barton, N.; Blaney, F. E.; Garland, S.; Tehan, B.; Wall, I. Seven transmembrane G protein-coupled receptors: insights for drug design from structure and modeling Compr. Med. Chem. II 2007, 4, 669-701
55. Garland, S.; Blaney, F. GPCR Homology Model Development and Application. In Burger's Medicinal Chemistry, Drug Discovery and Development, 7 th ed.; Abraham, D. J.; Rotella, D. P.; John Wiley and Sons: Hoboken, NJ, 2010; pp 279-300.
56. Sabio, M.; Jones, K.; Topiol, S. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds Bioorg. Med. Chem. Lett. 2008, 18 (20) 5391-5395
57. Mobarec, J. C.; Sanchez, R.; Filizola, M. Modern homology modeling of G-protein coupled receptors: which structural template to use? J. Med. Chem. 2009, 52 (16) 5207-5216
58. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-protein-coupled receptor Nature 2008, 454 (7203) 486-491
59. 2 adrenergic G-protein-coupled receptor Nature 2007, 450 (7168) 383-387 (Pubitemid 350126755)
60. 2-adrenergic G protein-coupled receptor Science 2007, 318 (5854) 1258-1265 (Pubitemid 350172884)
61. Robertson, N.; Jazayeri, A.; Errey, J.; Baig, A.; Hurrell, E.; Zhukov, A.; Langmead, C. J.; Weir, M.; Marshall, F. H. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery Neuropharmacology 2011, 60 (1) 36-44
62. Lopez, L.; Selent, J.; Ortega, R.; Masaguer, C. F.; Dominguez, E.; Areias, F.; Brea, J.; Loza, M. I.; Sanz, F.; Pastor, M. Synthesis, 3D-QSAR, and structural modeling of benzolactam derivatives with binding affinity for the D(2) and D(3) receptors ChemMedChem 2010, 5 (8) 1300-1317
63. Pooput, C.; Rosemond, E.; Karpiak, J.; Deflorian, F.; Vilar, S.; Costanzi, S.; Wess, J.; Kirk, K. L. Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines Bioorg. Med. Chem. 2009, 17 (23) 7987-7992
64. Kikkawa, H.; Isogaya, M.; Nagao, T.; Kurose, H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005 Mol. Pharmacol. 1998, 53 (1) 128-134 (Pubitemid 28068380)
65. 2A adenosine receptor bound to an antagonist Science 2008, 322 (5905) 1211-1217
66. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure, in press.
67. Katritch, V.; Rueda, M.; Lam, P. C.; Yeager, M.; Abagyan, R. GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex Proteins 2010, 78 (1) 197-211
68. Kim, S. K.; Gao, Z. G.; Van Rompaey, P.; Gross, A. S.; Chen, A.; Van Calenbergh, S.; Jacobson, K. A. Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists J. Med. Chem. 2003, 46 (23) 4847-4859 (Pubitemid 37352025)
69. Dal Ben, D.; Lambertucci, C.; Marucci, G.; Volpini, R.; Cristalli, G. Adenosine receptor modeling: What does the A2A crystal structure tell us? Curr. Top. Med. Chem. 2010, 10, 993-1018
70. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330 (6007) 1066-1071
71. Salchow, K.; Bond, M. E.; Evans, S. C.; Press, N. J.; Charlton, S. J.; Hunt, P. A.; Bradley, M. E. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor Br. J. Pharmacol. 2010, 159 (7) 1429-1439
72. Andrews, G.; Jones, C.; Wreggett, K. A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5 Mol. Pharmacol. 2008, 73 (3) 855-867 (Pubitemid 351397890)
73. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists Trends Pharmacol. Sci. 1989, 10 (6) 230-235 (Pubitemid 19146395)
74. Werge, T. M. Identification of an epitope in the substance P receptor important for recognition of the common carboxyl-terminal tachykinin sequence J. Biol. Chem. 1994, 269 (35) 22054-22058 (Pubitemid 24282127)
75. Veldkamp, C. T.; Seibert, C.; Peterson, F. C.; De la Cruz, N. B.; Haugner, J. C., 3rd; Basnet, H.; Sakmar, T. P.; Volkman, B. F. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12 Sci. Signaling 2008, 1 (37) ra4
76. Clark-Lewis, I.; Kim, K. S.; Rajarathnam, K.; Gong, J. H.; Dewald, B.; Moser, B.; Baggiolini, M.; Sykes, B. D. Structure-activity relationships of chemokines J. Leukocyte Biol. 1995, 57 (5) 703-711
77. Smith, S. O. Structure and activation of the visual pigment rhodopsin Annu. Rev. Biophys. 2010, 39, 309-328
78. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin Nature 2008, 454 (7201) 183-187 (Pubitemid 351969893)
79. Weis, W. I.; Kobilka, B. K. Structural insights into G-protein-coupled receptor activation Curr. Opin. Struct. Biol. 2008, 18 (6) 734-740
80. Rasmussen, S. G.; Choi, H. J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; Devree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; Schnapp, A.; Konetzki, I.; Sunahara, R. K.; Gellman, S. H.; Pautsch, A.; Steyaert, J.; Weis, W. I.; Kobilka, B. K. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor Nature 2011, 469 (7329) 175-180
81. Rosenbaum, D. M.; Zhang, C.; Lyons, J. A.; Holl, R.; Aragao, D.; Arlow, D. H.; Rasmussen, S. G.; Choi, H. J.; Devree, B. T.; Sunahara, R. K.; Chae, P. S.; Gellman, S. H.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Caffrey, M.; Gmeiner, P.; Kobilka, B. K. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex Nature 2011, 469 (7329) 236-240
82. Warne, T.; Moukhametzianov, R.; Baker, J. G.; Nehme, R.; Edwards, P. C.; Leslie, A. G.; Schertler, G. F.; Tate, C. G. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor Nature 2011, 469 (7329) 241-244
83. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z. G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound human A2A adenosine receptor Science 2011, 332 (6027) 322-327
84. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G.; Tate, C. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature [Online early access] DOI: 10.1038/nature10136. Published Online: May 18, 2011.
85. Parthier, C.; Reedtz-Runge, S.; Rudolph, R.; Stubbs, M. T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 2009, 34 (6) 303-310
86. Hansen, K. B.; Knop, F. K.; Holst, J. J.; Vilsboll, T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists Int. J. Clin. Pract. 2009, 63 (8) 1154-1160
87. Pioszak, A. A.; Parker, N. R.; Suino-Powell, K.; Xu, H. E. Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1 J. Biol. Chem. 2008, 283 (47) 32900-32912
88. Pioszak, A. A.; Xu, H. E. Molecular recognition of parathyroid hormone by its G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (13) 5034-5039 (Pubitemid 351738505)
89. Grace, C. R.; Perrin, M. H.; DiGruccio, M. R.; Miller, C. L.; Rivier, J. E.; Vale, W. W.; Riek, R. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (35) 12836-12841 (Pubitemid 39167545)
90. Foord, S. M.; Marshall, F. H. RAMPs: accessory proteins for seven transmembrane domain receptors Trends Pharmacol. Sci. 1999, 20 (5) 184-187
91. Ho, T. W.; Edvinsson, L.; Goadsby, P. J. CGRP and its receptors provide new insights into migraine pathophysiology Nat. Rev. Neurol. 2010, 6 (10) 573-582
92. ter Haar, E.; Koth, C. M.; Abdul-Manan, N.; Swenson, L.; Coll, J. T.; Lippke, J. A.; Lepre, C. A.; Garcia-Guzman, M.; Moore, J. M. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism Structure 2010, 18 (9) 1083-1093
93. Lisman, J. E.; Coyle, J. T.; Green, R. W.; Javitt, D. C.; Benes, F. M.; Heckers, S.; Grace, A. A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia Trends Neurosci. 2008, 31 (5) 234-242
94. Brabet, I.; Parmentier, M. L.; De Colle, C.; Bockaert, J.; Acher, F.; Pin, J. P. Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy- l -glutamate on all cloned metabotropic glutamate receptor subtypes Neuropharmacology 1998, 37 (8) 1043-1051 (Pubitemid 28401493)
95. Ishida, M.; Saitoh, T.; Shimamoto, K.; Ohfune, Y.; Shinozaki, H. A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord Br. J. Pharmacol. 1993, 109 (4) 1169-1177 (Pubitemid 23216788)
96. Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C. R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L.; Griffey, K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.; Schoepp, D. D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties J. Med. Chem. 1997, 40 (4) 528-537 (Pubitemid 27080033)
97. Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.; Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Tomlinson, R.; Lewis, R.; Griffey, K. R.; Tizzano, J. P.; Schoepp, D. D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2- aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors J. Med. Chem. 1999, 42 (6) 1027-1040 (Pubitemid 29153432)
98. Monn, J. A.; Massey, S. M.; Valli, M. J.; Henry, S. S.; Stephenson, G. A.; Bures, M.; Herin, M.; Catlow, J.; Giera, D.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0] hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors J. Med. Chem. 2007, 50 (2) 233-240 (Pubitemid 46147704)
99. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 2007, 13 (9) 1102-1107 (Pubitemid 47517511)
100. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor Nature 2000, 407 (6807) 971-977
101. Muto, T.; Tsuchiya, D.; Morikawa, K.; Jingami, H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (10) 3759-3764 (Pubitemid 47189144)
102. Topiol, S.; Sabio, M.; Uberti, M. Exploration of structure-based drug design opportunities for mGluRs Neuropharmacology 2011, 60 (1) 93-101
103. Costanzi, S.; Mamedova, L.; Gao, Z. G.; Jacobson, K. A. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling J. Med. Chem. 2004, 47 (22) 5393-5404 (Pubitemid 39382789)
104. Martin-Martinez, M.; Marty, A.; Jourdan, M.; Escrieut, C.; Archer, E.; Gonzalez-Muniz, R.; Garcia-Lopez, M. T.; Maigret, B.; Herranz, R.; Fourmy, D. Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor J. Med. Chem. 2005, 48 (15) 4842-4850 (Pubitemid 41033127)
105. Betz, S. F.; Lio, F. M.; Gao, Y.; Reinhart, G. J.; Guo, Z.; Mesleh, M. F.; Zhu, Y. F.; Struthers, R. S. Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling J. Med. Chem. 2006, 49 (21) 6170-6176 (Pubitemid 44595195)
106. Barry, G. D.; Suen, J. Y.; Low, H. B.; Pfeiffer, B.; Flanagan, B.; Halili, M.; Le, G. T.; Fairlie, D. P. A refined agonist pharmacophore for protease activated receptor 2 Bioorg. Med. Chem. Lett. 2007, 17 (20) 5552-5557 (Pubitemid 47391327)
107. Dukat, M.; Mosier, P. D.; Kolanos, R.; Roth, B. L.; Glennon, R. A. Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies J. Med. Chem. 2008, 51 (3) 603-611 (Pubitemid 351252288)
108. Boatman, P. D.; Richman, J. G.; Semple, G. Nicotinic acid receptor agonists J. Med. Chem. 2008, 51 (24) 7653-7662
109. Kane, B. E.; McCurdy, C. R.; Ferguson, D. M. Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor J. Med. Chem. 2008, 51 (6) 1824-1830 (Pubitemid 351438865)
110. Harterich, S.; Koschatzky, S.; Einsiedel, J.; Gmeiner, P. Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1 Bioorg. Med. Chem. 2008, 16 (20) 9359-9368
111. Cavasotto, C. N.; Orry, A. J.; Murgolo, N. J.; Czarniecki, M. F.; Kocsi, S. A.; Hawes, B. E.; O'Neill, K. A.; Hine, H.; Burton, M. S.; Voigt, J. H.; Abagyan, R. A.; Bayne, M. L.; Monsma, F. J., Jr. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening J. Med. Chem. 2008, 51 (3) 581-588 (Pubitemid 351252286)
112. Engel, S.; Skoumbourdis, A. P.; Childress, J.; Neumann, S.; Deschamps, J. R.; Thomas, C. J.; Colson, A. O.; Costanzi, S.; Gershengorn, M. C. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists J. Am. Chem. Soc. 2008, 130 (15) 5115-5123 (Pubitemid 351537071)
113. McRobb, F. M.; Capuano, B.; Crosby, I. T.; Chalmers, D. K.; Yuriev, E. Homology modeling and docking evaluation of aminergic G protein-coupled receptors J. Chem. Inf. Model. 2010, 50 (4) 626-637
114. Kneissl, B.; Leonhardt, B.; Hildebrandt, A.; Tautermann, C. S. Revisiting automated G-protein coupled receptor modeling: the benefit of additional template structures for a neurokinin-1 receptor model J. Med. Chem. 2009, 52 (10) 3166-3173
115. Pecic, S.; Makkar, P.; Chaudhary, S.; Reddy, B. V.; Navarro, H. A.; Harding, W. W. Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies Bioorg. Med. Chem. 2010, 18 (15) 5562-5575
116. de la Fuente, T.; Martin-Fontecha, M.; Sallander, J.; Benhamu, B.; Campillo, M.; Medina, R. A.; Pellissier, L. P.; Claeysen, S.; Dumuis, A.; Pardo, L.; Lopez-Rodriguez, M. L. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation J. Med. Chem. 2010, 53 (3) 1357-1369
117. Wacker, D.; Fenalti, G.; Brown, M. A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R. C. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography J. Am. Chem. Soc. 2010, 132 (33) 11443-11445
118. Kolb, P.; Rosenbaum, D. M.; Irwin, J. J.; Fung, J. J.; Kobilka, B. K.; Shoichet, B. K. Structure-based discovery of beta2-adrenergic receptor ligands Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (16) 6843-6848
119. 2-adrenergic receptor J. Med. Chem. 2008, 51 (10) 2907-2914 (Pubitemid 351706019)
120. de Graaf, C.; Rognan, D. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor J. Med. Chem. 2008, 51 (16) 4978-4985
121. Soriano-Ursua, M. A.; Trujillo-Ferrara, J. G.; Correa-Basurto, J. Homology modeling and flex-ligand docking studies on the guinea pig beta(2) adrenoceptor: structural and experimental similarities/ differences with the human beta(2) J. Mol. Model. 2009, 15 (10) 1203-1211
122. Hattori, K.; Orita, M.; Toda, S.; Imanishi, M.; Itou, S.; Nakajima, Y.; Tanabe, D.; Washizuka, K.; Araki, T.; Sakurai, M.; Matsui, S.; Imamura, E.; Ueshima, K.; Yamamoto, T.; Yamamoto, N.; Ishikawa, H.; Nakano, K.; Unami, N.; Hamada, K.; Matsumura, Y.; Takamura, F. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6 Bioorg. Med. Chem. Lett. 2009, 19 (16) 4679-4683
123. Gao, Z. G.; Chen, A.; Barak, D.; Kim, S. K.; Muller, C. E.; Jacobson, K. A. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor J. Biol. Chem. 2002, 277 (21) 19056-19063 (Pubitemid 34952470)
124. Michielan, L.; Bolcato, C.; Federico, S.; Cacciari, B.; Bacilieri, M.; Klotz, K. N.; Kachler, S.; Pastorin, G.; Cardin, R.; Sperduti, A.; Spalluto, G.; Moro, S. Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: an alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites Bioorg. Med. Chem. 2009, 17 (14) 5259-5274
125. Colotta, V.; Lenzi, O.; Catarzi, D.; Varano, F.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Ciampi, O.; Pugliese, A. M.; Traini, C.; Pedata, F.; Morizzo, E.; Moro, S. Pyrido[2,3- e ]-1,2,4-triazolo[4,3- a ]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies J. Med. Chem. 2009, 52 (8) 2407-2419
126. Lenzi, O.; Colotta, V.; Catarzi, D.; Varano, F.; Poli, D.; Filacchioni, G.; Varani, K.; Vincenzi, F.; Borea, P. A.; Paoletta, S.; Morizzo, E.; Moro, S. 2-Phenylpyrazolo[4,3- d ]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition J. Med. Chem. 2009, 52 (23) 7640-7652
127. Cheong, S. L.; Dolzhenko, A.; Kachler, S.; Paoletta, S.; Federico, S.; Cacciari, B.; Klotz, K. N.; Moro, S.; Spalluto, G.; Pastorin, G. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition J. Med. Chem. 2010, 53 (8) 3361-3375
128. Cheng, F.; Xu, Z.; Liu, G.; Tang, Y. Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods Eur. J. Med. Chem. 2010, 45 (8) 3459-3471
129. Jaakola, V. P.; Ijzerman, A. P. The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design Curr. Opin. Struct. Biol. 2010, 20 (4) 401-414
130. Michino, M.; Abola, E.; Brooks, C. L., 3rd; Dixon, J. S.; Moult, J.; Stevens, R. C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR dock 2008 Nat. Rev. Drug Discovery 2009, 8 (6) 455-463
131. Carlsson, J.; Yoo, L.; Gao, Z. G.; Irwin, J. J.; Shoichet, B. K.; Jacobson, K. A. Structure-based discovery of A(2A) adenosine receptor ligands J. Med. Chem. 2010, 53, 3748-3755
132. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9 (10) 430-431 (Pubitemid 38510559)
133. Ivanov, A. A.; Barak, D.; Jacobson, K. A. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure J. Med. Chem. 2009, 52 (10) 3284-3292
134. Pastorin, G.; Federico, S.; Paoletta, S.; Corradino, M.; Cateni, F.; Cacciari, B.; Klotz, K. N.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G.; Moro, S. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5- a ][1,3,5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand-receptor recognition process Bioorg. Med. Chem. 2010, 18 (7) 2524-2536
135. Hobrath, J. V.; Wang, S. Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling J. Med. Chem. 2006, 49 (15) 4470-4476 (Pubitemid 44162673)
136. Ehrlich, K.; Gotz, A.; Bollinger, S.; Tschammer, N.; Bettinetti, L.; Harterich, S.; Hubner, H.; Lanig, H.; Gmeiner, P. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding J. Med. Chem. 2009, 52 (15) 4923-4935
137. Allegretti, M.; Bertini, R.; Cesta, M. C.; Bizzarri, C.; Di Bitondo, R.; Di Cioccio, V.; Galliera, E.; Berdini, V.; Topai, A.; Zampella, G.; Russo, V.; Di Bello, N.; Nano, G.; Nicolini, L.; Locati, M.; Fantucci, P.; Florio, S.; Colotta, F. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors J. Med. Chem. 2005, 48 (13) 4312-4331 (Pubitemid 40884935)
138. Spalding, T. A.; Trotter, C.; Skjaerbaek, N.; Messier, T. L.; Currier, E. A.; Burstein, E. S.; Li, D.; Hacksell, U.; Brann, M. R. Discovery of an ectopic activation site on the M(1) muscarinic receptor Mol. Pharmacol. 2002, 61 (6) 1297-1302 (Pubitemid 34575739)
139. Langmead, C. J.; Fry, V. A.; Forbes, I. T.; Branch, C. L.; Christopoulos, A.; Wood, M. D.; Herdon, H. J. Probing the molecular mechanism of interaction between 4- n -butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist Mol. Pharmacol. 2006, 69 (1) 236-246 (Pubitemid 43048910)
140. Lebon, G.; Langmead, C. J.; Tehan, B. G.; Hulme, E. C. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors Mol. Pharmacol. 2009, 75 (2) 331-341
141. Budzik, B.; Garzya, V.; Shi, D.; Walker, G.; Lauchart, Y.; Lucas, A. J.; Rivero, R. A.; Langmead, C. J.; Watson, J.; Wu, Z.; Forbes, I. T.; Jin, J. 2′ Biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling Bioorg. Med. Chem. Lett. 2010, 20 (12) 3545-3549
142. Ma, L.; Seager, M. A.; Wittmann, M.; Jacobson, M.; Bickel, D.; Burno, M.; Jones, K.; Graufelds, V. K.; Xu, G.; Pearson, M.; McCampbell, A.; Gaspar, R.; Shughrue, P.; Danziger, A.; Regan, C.; Flick, R.; Pascarella, D.; Garson, S.; Doran, S.; Kreatsoulas, C.; Veng, L.; Lindsley, C. W.; Shipe, W.; Kuduk, S.; Sur, C.; Kinney, G.; Seabrook, G. R.; Ray, W. J. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (37) 15950-15955
143. Deng, Q.; Frie, J. L.; Marley, D. M.; Beresis, R. T.; Ren, N.; Cai, T. Q.; Taggart, A. K.; Cheng, K.; Carballo-Jane, E.; Wang, J.; Tong, X.; Waters, M. G.; Tata, J. R.; Colletti, S. L. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists Bioorg. Med. Chem. Lett. 2008, 18 (18) 4963-4967
144. Gonzalez, A.; Duran, L. S.; Araya-Secchi, R.; Garate, J. A.; Pessoa-Mahana, C. D.; Lagos, C. F.; Perez-Acle, T. Computational modeling study of functional microdomains in cannabinoid receptor type 1 Bioorg. Med. Chem. 2008, 16 (8) 4378-4389 (Pubitemid 351552046)
145. Diaz, P.; Phatak, S. S.; Xu, J.; Astruc-Diaz, F.; Cavasotto, C. N.; Naguib, M. 6-Methoxy- N -alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction J. Med. Chem. 2009, 52 (2) 433-444
146. Szabo, G.; Kiss, R.; Payer-Lengyel, D.; Vukics, K.; Szikra, J.; Baki, A.; Molnar, L.; Fischer, J.; Keseru, G. M. Hit-to-lead optimization of pyrrolo[1,2- a ]quinoxalines as novel cannabinoid type 1 receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19 (13) 3471-3475
147. Lange, J. H.; Coolen, H. K.; van der Neut, M. A.; Borst, A. J.; Stork, B.; Verveer, P. C.; Kruse, C. G. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism J. Med. Chem. 2010, 53 (3) 1338-1346
148. El Bakali, J.; Muccioli, G. G.; Renault, N.; Pradal, D.; Body-Malapel, M.; Djouina, M.; Hamtiaux, L.; Andrzejak, V.; Desreumaux, P.; Chavatte, P.; Lambert, D. M.; Millet, R. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series J. Med. Chem. 2010, 53 (22) 7918-7931
149. Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis J. Med. Chem. 2006, 49 (3) 984-994 (Pubitemid 43221646)
150. Antel, J.; Gregory, P. C.; Nordheim, U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders J. Med. Chem. 2006, 49 (14) 4008-4016 (Pubitemid 44036646)
151. Lin, L. S.; Ha, S.; Ball, R. G.; Tsou, N. N.; Castonguay, L. A.; Doss, G. A.; Fong, T. M.; Shen, C. P.; Xiao, J. C.; Goulet, M. T.; Hagmann, W. K. Conformational analysis and receptor docking of N -[(1 S,2 S)-3-(4-chlorophenyl) -2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2 -{[5-(trifluoromethyl)pyridin-2- yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist J. Med. Chem. 2008, 51 (7) 2108-2114 (Pubitemid 351503266)
152. Kuduk, S. D.; Di Marco, C. N.; Chang, R. K.; Wood, M. R.; Kim, J. J.; Schirripa, K. M.; Murphy, K. L.; Ransom, R. W.; Tang, C.; Torrent, M.; Ha, S.; Prueksaritanont, T.; Pettibone, D. J.; Bock, M. G. 5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists Bioorg. Med. Chem. Lett. 2006, 16 (10) 2791-2795
153. Huang, H.; Player, M. R. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain J. Med. Chem. 2010, 53 (15) 5383-5399
154. Su, D. S.; Markowitz, M. K.; DiPardo, R. M.; Murphy, K. L.; Harrell, C. M.; O'Malley, S. S.; Ransom, R. W.; Chang, R. S.; Ha, S.; Hess, F. J.; Pettibone, D. J.; Mason, G. S.; Boyce, S.; Freidinger, R. M.; Bock, M. G. Discovery of a potent, non-peptide bradykinin B1 receptor antagonist J. Am. Chem. Soc. 2003, 125 (25) 7516-7517 (Pubitemid 36750263)
155. Sela, I.; Golan, G.; Strajbl, M.; Rivenzon-Segal, D.; Bar-Haim, S.; Bloch, I.; Inbal, B.; Shitrit, A.; Ben-Zeev, E.; Fichman, M.; Markus, Y.; Marantz, Y.; Senderowitz, H.; Kalid, O. G protein coupled receptors -in silico drug discovery and design Curr. Top. Med. Chem. 2010, 10 (6) 638-656
156. Senderowitz, H.; Marantz, Y. G protein-coupled receptors: target-based in silico screening Curr. Pharm. Des. 2009, 15 (35) 4049-4068
157. Zhukov, A.; Andrews, S. P.; Errey, J. C.; Robertson, N.; Tehan, B.; Mason, J. S.; Marshall, F. H.; Weir, M.; Congreve, M. J. Med. Chem. 2011, DOI: 10.1021/jm2003798.
158. Deupi, X.; Dolker, N.; Lopez-Rodriguez, M. L.; Campillo, M.; Ballesteros, J. A.; Pardo, L. Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity Curr. Top. Med. Chem. 2007, 7 (10) 991-998 (Pubitemid 47044747)
159. Radestock, S.; Weil, T.; Renner, S. Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring J. Chem. Inf. Model 2008, 48 (5) 1104-1117
160. Li, Y. Y.; Hou, T. J.; Goddard, W. A., 3rd. Computational modeling of structure-function of G protein-coupled receptors with applications for drug design Curr. Med. Chem. 2010, 17 (12) 1167-1180
161. Yarnitzky, T.; Levit, A.; Niv, M. Y. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise Curr. Opin. Drug Discovery Dev. 2010, 13 (3) 317-325
162. Klabunde, T.; Giegerich, C.; Evers, A. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening J. Med. Chem. 2009, 52 (9) 2923-2932
163. Topiol, S.; Sabio, M. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery Bioorg. Med. Chem. Lett. 2008, 18 (5) 1598-1602 (Pubitemid 351318251)
164. Higgs, C.; Beuming, T.; Sherman, W. Hydration site thermodynamics explain SARs for triazolylpurines analogues binding to the A2A receptor ACS Med. Chem. Lett. 2010, 1, 160-164
165. Bywater, R. P. Location and nature of the residues important for ligand recognition in G-protein coupled receptors J. Mol. Recognit. 2005, 18 (1) 60-72 (Pubitemid 40059571)
166. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of privileged structures by G-protein coupled receptors J. Med. Chem. 2004, 47 (4) 888-899 (Pubitemid 38176791)
167. Rosenkilde, M. M.; Benned-Jensen, T.; Frimurer, T. M.; Schwartz, T. W. The minor binding pocket: a major player in 7TM receptor activation Trends Pharmacol. Sci. 2010, 31 (12) 567-574
168. Akritopoulou-Zanze, I.; Hajduk, P. J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors Drug Discovery Today 2009, 14 (5-6) 291-297
169. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51 (13) 3661-3680 (Pubitemid 351956496)
170. Chessari, G.; Woodhead, A. J. From fragment to clinical candidate-a historical perspective Drug Discovery Today 2009, 14 (13-14) 668-675
171. Schulz, M. N.; Hubbard, R. E. Recent progress in fragment-based lead discovery Curr. Opin. Pharmacol. 2009, 9 (5) 615-621
172. Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H.; Geschwindner, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olsson, L. L.; Sanganee, H.; Shapiro, A. B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes Curr. Top. Med. Chem. 2007, 7 (16) 1600-1629 (Pubitemid 350131017)
173. Bartoschek, S.; Klabunde, T.; Defossa, E.; Dietrich, V.; Stengelin, S.; Griesinger, C.; Carlomagno, T.; Focken, I.; Wendt, K. U. Drug design for G-protein-coupled receptors by a ligand-based NMR method Angew. Chem., Int. Ed. 2010, 49 (8) 1426-1429
174. Congreve, M.; Rich, R. L.; Myszka, D. G.; Figaroa, F.; Siegal, G.; Marshall, F. H. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods Methods Enzymol. 2011, 493, 115-136
175. Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E. M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (9) 5982-5987 (Pubitemid 34493251)
176. Li, J.; Edwards, P. C.; Burghammer, M.; Villa, C.; Schertler, G. F. Structure of bovine rhodopsin in a trigonal crystal form J. Mol. Biol. 2004, 343 (5) 1409-1438 (Pubitemid 39387834)
177. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure J. Mol. Biol. 2004, 342 (2) 571-583 (Pubitemid 39149759)
178. Salom, D.; Lodowski, D. T.; Stenkamp, R. E.; Le Trong, I.; Golczak, M.; Jastrzebska, B.; Harris, T.; Ballesteros, J. A.; Palczewski, K. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (44) 16123-16128 (Pubitemid 44715162)
179. Standfuss, J.; Xie, G.; Edwards, P. C.; Burghammer, M.; Oprian, D. D.; Schertler, G. F. Crystal structure of a thermally stable rhodopsin mutant J. Mol. Biol. 2007, 372 (5) 1179-1188 (Pubitemid 47381449)
180. Shimamura, T.; Hiraki, K.; Takahashi, N.; Hori, T.; Ago, H.; Masuda, K.; Takio, K.; Ishiguro, M.; Miyano, M. Crystal structure of squid rhodopsin with intracellularly extended cytoplasmic region J. Biol. Chem. 2008, 283 (26) 17753-17756
181. Murakami, M.; Kouyama, T. Crystal structure of squid rhodopsin Nature 2008, 453 (7193) 363-367 (Pubitemid 351693128)
182. 2-adrenergic receptor Structure 2008, 16 (6) 897-905 (Pubitemid 351778384)
183. Bokoch, M. P.; Zou, Y.; Rasmussen, S. G.; Liu, C. W.; Nygaard, R.; Rosenbaum, D. M.; Fung, J. J.; Choi, H. J.; Thian, F. S.; Kobilka, T. S.; Puglisi, J. D.; Weis, W. I.; Pardo, L.; Prosser, R. S.; Mueller, L.; Kobilka, B. K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor Nature 2010, 463 (7277) 108-112
184. Makino, C. L.; Riley, C. K.; Looney, J.; Crouch, R. K.; Okada, T. Binding of more than one retinoid to visual opsins Biophys. J. 2010, 99 (7) 2366-2373
185. Choe, H. W.; Kim, Y. J.; Park, J. H.; Morizumi, T.; Pai, E. F.; Krauss, N.; Hofmann, K. P.; Scheerer, P.; Ernst, O. P. Crystal structure of metarhodopsin II Nature 2011, 471 (7340) 651-655